Active Studies
Parkinson's Studies
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
A PET Imaging Study Using NeuroEXPLORER to compare how well [18F] PI-2620, a PET radiotracer targeting Tau protein, binds to brain regions in people with Parkinson's disease, Progressive Supranuclear Palsy, Corticobasal Syndrome, and healthy volunteers.
-
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease.
-
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI)
The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort.
-
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTs
Longitudinal evaluation of [18F] AV-133 as a PET radioligand for detecting disease progression in patients with Parkinson disease.
-
Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's
A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson’s Disease.
-
Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with a 52 Week Blinded Extension (Pasadena)
Alzheimer's Studies
-
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
-
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Diseas
Healthy Volunteer Studies
-
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI)- Healthy Volunteers
The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study sponsored by the Michael J Fox Foundation to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls
-
Brain Imaging Studies for Healthy Volunteers
Many of the symptoms in Alzheimer disease and Parkinson disease relate to changes in specific neurochemicals in the brain. The imaging research program at IND is developing techniques to all for imaging these neurochemical changes. Healthy volunteers are critical to this research as it is necessary to compare the changes in the brain that occur with the brain of healthy individuals.
Huntington’s Disease
No Active Studies At This Time
ClinicalTrials.gov
www.ClinicalTrials.gov is a government sponsored website which provides listings of clinical research studies for all diseases, and gives contact information. You can find the most update-to-date information on IND studies using the link below.